.AN2 Rehabs is reviewing its service in action to poor midphase records, promising to lay off half i...
.Merck & Co. is actually paying out $700 million upfront to challenge Amgen in a blood cancer cel...
.With Gilead Sciences almost an FDA selection for its own liver disease medicine seladelpar, the fir...
.CEO David Ricks may observe the firms setting up tents at basecamp behind Eli Lilly in an attempt t...
.Bed mattress Liquidators has turned Entero Therapies white as a slab. The financial institution ord...
.Exelixis is quiting on its own cells element (TF)- targeting antibody-drug conjugate after ending t...
.3 weeks after Roche's Genentech system left an SHP2 inhibitor treaty, Relay Rehab has validated tha...
.Stoke Therapies' Dravet disorder drug has actually been actually freed from a partial hold, getting...
.Fierce Biotech Partner Editor Gabrielle Masson showed the 2024 class of Strong 15 winners on the fl...
.Merck & Co. has promptly made back a number of the prices of its Harpoon Rehabs acquistion, pull...